In a survey of 2,173 patients who discontinued the use of GLP-1 drugs, a majority of the patients identified two main areas of concern: the GI-related discomfort or the negativity associated with injections: In a separate survey published in March 2026, of 1,536 Canadians and 1,012 Americans, Leger Healthcare market research reported a number of key findings related to GLP-1 use and intentions across North America: 11% of American adults and 8% of Canadian adults are currently taking a GLP-1 prescription Extrapolated, this suggests that 28M+ American adults and 3M+ Canadian adults are currently using GLP-1 prescriptions 12% of Americans and 6% of Canadians are interested in taking a GLP-1 prescription 71% of Americans and 58% of Canadians cite weight loss as a primary reason for their interest in GLP-1 drugs Given that nearly two-thirds of GLP-1 customers focused on weight loss tend to discontinue use of the drugs within the first year, Lexaria knew that our attempts to improve the patient experience could provide a profoundly positive business case

GI side effects: Continue to decrease over time
Thigh injections tend to absorb slightly slower than abdominal injections, which some researchers find helpful for managing initial side effects
Athletes subject to testing (Olympic, NCAA, IFBB Pro League, etc.) should not use Ipamorelin unless they have a documented medical exemption